Evaluation of intratumoural heterogeneity on 18F-FDG PET/CT for characterization of peripheral nerve sheath tumours in neurofibromatosis type 1

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue 5, 2013, Pages 685-692

  Salamon, Johannes ^a   Derlin, Thorsten ^a   Bannas, Peter ^a   Busch, Jasmin D ^a   Herrmann, Jochen ^a   Bockhorn, Maximilian ^a   Hagel, Christian ^a   Friedrich, Reinhard E ^a   Adam, Gerhard ^a   Mautner, Victor F ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Heterogeneity; MPNST; Neurofibromatosis; NF1; PET CT; Sarcoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GASTROLUX CT; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER SIZE; CHILD; CLINICAL ARTICLE; CLINICAL OBSERVATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CYSTADENOMA; DRUG UPTAKE; FEMALE; FOLLOW UP; GANGLIONEUROMA; GASTROINTESTINAL STROMAL TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE RECONSTRUCTION; MALE; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MALIGNANT TRANSFORMATION; MIDDLE AGED; NEUROFIBROMATOSIS; OUTCOME ASSESSMENT; PET-CT SCANNER; PREDICTIVE VALUE; PRESCHOOL CHILD; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY; YOUNG ADULT; COMPUTER ASSISTED TOMOGRAPHY; METABOLISM; MULTIMODAL IMAGING; NERVE SHEATH TUMOR; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; SCINTISCANNING; TRANSPORT AT THE CELLULAR LEVEL; DIAGNOSTIC USE;

ADOLESCENT; ADULT; AGED; BIOLOGICAL TRANSPORT; CHILD; CHILD, PRESCHOOL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NERVE SHEATH NEOPLASMS; NEUROFIBROMATOSIS 1; POSITRON-EMISSION TOMOGRAPHY; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 84883067150     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2314-6     Document Type: Article

References (25)

1. Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis. J Med Genet 2002;39(5):311-4.
2. Grobmyer SR, Reith JD, Shahlaee A, Bush CH, Hochwald SN. Malignant peripheral nerve sheath tumor: molecular pathogenesis and current management considerations. J Surg Oncol 2008;97 (4):340-9.
3. Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res 2002;62(5):1573-7.
4. Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 1986;57(10):2006-21.
5. Korf BR. Plexiform neurofibromas. Am J Med Genet 1999;89 (1):31-7.
6. Mautner VF, Hartmann M, Kluwe L, Friedrich RE, Fünsterer C. MRI growth patterns of plexiform neurofibromas in patients with neurofibromatosis type 1. Neuroradiology 2006;48(3):160-5.
7. Warbey VS, Ferner RE, Dunn JT, Calonje E, O'Doherty MJ. [18F] FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1. Eur J Nucl Med Mol Imaging 2009;36(5):751-7.
8. Rasmussen SA, Yang Q, Friedman JM. Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am J Hum Genet 2001;68(5):1110-8.
9. Ferner RE, Golding JF, Smith M, Calonje E, JanW, Sanjayanathan V, et al. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol 2008;19 (2):390-4.
10. Brenner W, Friedrich RE, Gawad KA, Hagel C, von Deimling A, de Wit M, et al. Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours. Eur J Nucl Med Mol Imaging 2006;33(4):428-32.
11. Benz MR, Czernin J, Dry SM, Tap WD, Allen-Auerbach MS, Elashoff D, et al. Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign. Cancer 2010;116(2):451-8.
12. Wasa J, Nishida Y, Tsukushi S, Shido Y, Sugiura H, Nakashima H, et al. MRI features in the differentiation of malignant peripheral nerve sheath tumors and neurofibromas. AJR Am J Roentgenol 2010;194(6):1568-74.
13. Friedrich RE, Kluwe L, Fünsterer C, Mautner VF. Malignant peripheral nerve sheath tumors (MPNST) in neurofibromatosis type 1 (NF1): diagnostic findings on magnetic resonance images and mutation analysis of the NF1 gene. Anticancer Res 2005;25 (3A):1699-702.
14. NIH Office of Medical Applications of Research. Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 1988;45(5):575-8.
15. Trojani M, Contesso G, Coindre JM, Rouesse J, Bui NB, de Mascarel A, et al. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer 1984;33(1):37-42.
16. Lin BT, Weiss LM, Medeiros LJ. Neurofibroma and cellular neurofibroma with atypia: a report of 14 tumors. Am J Surg Pathol 1997;21(12):1443-9.
17. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33(1):159-74.
18. Cardona S, Schwarzbach M, Hinz U, Dimitrakopoulou-Strauss A, Attigah N, Mechtersheimer section sign G, et al. Evaluation of F18-deoxyglucose positron emission tomography (FDG-PET) to assess the nature of neurogenic tumours. Eur J Surg Oncol 2003;29 (6):536-41.
19. Matsumine A, Kusuzaki K, Nakamura T, Nakazora S, Niimi R, Matsubara T, et al. Differentiation between neurofibromas and malignant peripheral nerve sheath tumors in neurofibromatosis 1 evaluated by MRI. J Cancer Res Clin Oncol 2009;135(7):891-900.
20. 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med 2011;52 (3):369-78.
21. van Velden FH, Cheebsumon P, Yaqub M, Smit EF, Hoekstra OS, Lammertsma AA, et al. Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studies. Eur J Nucl Med Mol Imaging 2011;38(9):1636-47.
22. Chicklore S, Goh V, Siddique M, Roy A, Marsden PK, Cook GJ. Quantifying tumour heterogeneity in (18)F-FDG PET/CT imaging by texture analysis. Eur J Nucl Med Mol Imaging 2013;40:133-40.
23. Buchbender C, Heusner TA, Lauenstein TC, Bockisch A, Antoch G. Oncologic PET/MRI, part 2: bone tumors, soft-tissue tumors, melanoma, and lymphoma. J Nucl Med 2012;53(8):1244-52.
24. Buck AK, Herrmann K, Büschenfelde CM, Juweid ME, Bischoff M, Glatting G, et al. Imaging bone and soft tissue tumors with the proliferation marker [18F]fluorodeoxythymidine. Clin Cancer Res 2008;14(10):2970-7.
25. Eary JF, Link JM, Muzi M, Conrad EU, Mankoff DA, White JK, et al. Multiagent PET for risk characterization in sarcoma. J Nucl Med 2011;52(4):541-6.